CHECKPOINT

作品数：720被引量：1395H指数：15
导出分析报告
相关领域：医药卫生自动化与计算机技术更多>>
相关作者：段红刘穆进张彩田志刚景年财更多>>
相关机构：上海大学华中科技大学国防科学技术大学CheckPoint软件技术有限公司更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=World Journal of Clinical Oncologyx
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature
《World Journal of Clinical Oncology》2025年第4期298-311,共14页Lou-Lu Gao Dong-Ni Gao Hong-Tu Yuan Wen-Qiang Chen Jing Yang Jie-Qiong Peng 
BACKGROUNDGastrointestinal neuroendocrine carcinoma (GI NEC) has a low incidence rate andpoor prognosis. Most patients already have metastatic disease when they arediagnosed. Platinum chemotherapy is the main means of...
关键词：Gastrointestinal neuroendocrine carcinoma Immune checkpoint inhibitors Angiogenesis inhibitors Combination therapy Case report 
Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma
《World Journal of Clinical Oncology》2025年第3期30-39,共10页Zhuo-Jun Wei Lin Wang Rui-Qi Wang Yu Wang Huan Chen Hong-Lian Ma Yu-Jin Xu 
Supported by Natural Science Foundation of Zhejiang Province,China,No.LGF21H160005;Zhejiang Medical and Health Science and Technology Project,China,No.2024KY049.
BACKGROUND Esophageal squamous cell carcinoma(ESCC)is a common malignancy in China,often diagnosed at an advanced stage,with poor prognosis.Standard treatments such as definitive chemoradiotherapy offer limited surviv...
关键词：Esophageal squamous cell carcinoma RADIOTHERAPY Immune checkpoint inhibitors CHEMOTHERAPY Patient safety Treatment outcome 
Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
《World Journal of Clinical Oncology》2024年第8期1002-1020,共19页An-Jie Guo Qing-Yuan Deng Pan Dong Lian Zhou Lei Shi 
Supported by The Fundamental Research Funds for the Central Universities,No.2019CDYGYB024;The National Natural Science Foundation of China,No.31300726;The Chongqing Primary and Middle School Innovation Talent Training Project,No.CY220113.
Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irA...
关键词：IMMUNOTHERAPY Immune checkpoint inhibitors Immune-related adverse events Biomarkers CANCERS 
PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum:Two case reports
《World Journal of Clinical Oncology》2024年第3期456-463,共8页Yi-Nan Shi Xiao-Rui Zhang Wei-Yu Ma Jing Lian Yan-Feng Liu Yi-Fan Li Wen-Hui Yang 
BACKGROUND SMARCA4 is a component of chromatin remodeling of SWItch/sucrose-nonfermenting(SWI/SNF)complexes and plays an essential role in oncogenesis.SMARCA4-deficient malignancies arising from the gastrointestinal t...
关键词：SMARCA4 deficiency Undifferentiated carcinomas CHEMOTHERAPY Programmed death 1 Immune checkpoint inhibitors Case report 
Immunotherapy in glioblastoma treatment:Current state and future prospects被引量：1
《World Journal of Clinical Oncology》2023年第4期138-159,共22页Samuel Luca Rocha Pinheiro Fabian Fellipe Bueno Lemos Hanna Santos Marques Marcel Silva Luz Luís Guilherme de Oliveira Silva Clara Faria Souza Mendes dos Santos Karolaine da Costa Evangelista Mariana Santos Calmon Matheus Sande Loureiro Fabrício Freire de Melo 
Supported by the Scientific Initiation Scholarship Programme(PIBIC)of National Council for Scientific and Technological Development,CNPq,Brazil;the Scientific Initiation Scholarship Programme(PIBIC)of Bahia State Research Support Foundation,FAPESB,Brazil.
Glioblastoma remains as the most common and aggressive malignant brain tumor,standing with a poor prognosis and treatment prospective.Despite the aggressive standard care,such as surgical resection and chemoradiation,...
关键词：GLIOBLASTOMA IMMUNOTHERAPY Tumor microenvironment Chimeric antigen receptor T cell Oncolytic viruses Immune-checkpoint inhibitors Brain cancer 
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer:A natural process of advanced tumor progression?
《World Journal of Clinical Oncology》2022年第9期729-737,共9页Mo-Xuan Wang Shu-Yue Gao Fan Yang Run-Jia Fan Qin-Na Yang Tian-Lan Zhang Nian-Song Qian Guang-Hai Dai 
Immunotherapy has shown great promise in treating various types of malignant tumors.However,some patients with gastrointestinal cancer have been known to experience rapid disease progression after treatment,a situatio...
关键词：Hyperprogressive IMMUNOTHERAPY Natural process Gastric cancer Colorectal cancer 
Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer被引量：1
《World Journal of Clinical Oncology》2022年第7期641-651,共11页Ako Gannichida Yusuke Nakazawa Akira Kageyama Hirofumi Utsumi Kazuyoshi Kuwano Takashi Kawakubo 
BACKGROUND Low neutrophil-to-lymphocyte ratio(NLR)has been shown to be associated with a favorable therapeutic response to nivolumab.The activation of immunocompetent cells such as lymphocytes exhibits an antitumor ef...
关键词：Nivolumab HYPOTHYROIDISM Immune checkpoint inhibitors Immune-related adverse event Neutrophil-to-lymphocyte ratio 
Immunotherapy for advanced hepatocellular carcinoma:From clinical trials to real-world data and future advances被引量：2
《World Journal of Clinical Oncology》2022年第6期448-472,共25页Kathrine S Rallis Dimitrios Makrakis Ioannis A Ziogas Georgios Tsoulfas 
Hepatocellular carcinoma(HCC)is a leading cause of cancer-associated mortality worldwide.HCC is an inflammation-associated immunogenic cancer that frequently arises in chronically inflamed livers.Advanced HCC is manag...
关键词：Hepatocellular carcinoma Liver cancer IMMUNOTHERAPY Immune checkpoint inhibitors Clinical trials Real-world data 
Neoadjuvant treatment in non-small cell lung cancer:New perspectives with the incorporation of immunotherapy被引量：1
《World Journal of Clinical Oncology》2022年第5期314-322,共9页Carlos Aguado Luis Chara Mónica Antonanzas Jose Maria Matilla Gonzalez Unai Jiménez Raul Hernanz Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Counago 
The aim of neoadjuvant treatment in non-small cell lung cancer(NSCLC)is to eliminate micrometastatic disease to facilitate surgical resection.Neoadjuvant chemotherapy(ChT)in localised NSCLC has numerous advantages ove...
关键词：Non-small cell lung cancer NEOADJUVANT Immune checkpoint inhibitors IMMUNOTHERAPY Anti-PD1 Anti-PD-L1 Complete pathological response 
Immune checkpoint inhibitors in head and neck squamous cell carcinoma:A systematic review of phase-3 clinical trials
《World Journal of Clinical Oncology》2022年第5期388-411,共24页Jissy Vijo Poulose Cessal Thommachan Kainickal 
BACKGROUND The outcomes of patients diagnosed with head and neck squamous cell carcinoma(HNSCC)who are not candidates for local salvage therapy and of those diagnosed with recurrent or metastatic disease are dismal.A ...
关键词：Head and neck squamous cell carcinoma Recurrent/metastatic head and neck squamous cell carcinoma Locally advanced head and neck squamous cell carcinoma Immune checkpoint inhibitors Immunotherapy Monoclonal antibody 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部